

Kuniaki Arai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7583013/publications.pdf>

Version: 2024-02-01

51
papers

992
citations

430874

18
h-index

477307

29
g-index

55
all docs

55
docs citations

55
times ranked

1548
citing authors

#	ARTICLE	IF	CITATIONS
1	Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells. <i>Nature Communications</i> , 2022, 13, .	12.8	8
2	Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 190-200.	3.4	9
3	The characteristics of the immune cell profiles in peripheral blood in cholangiocarcinoma patients. <i>Hepatology International</i> , 2021, 15, 695-706.	4.2	7
4	Serum Laminin $\hat{1}^{32}$ Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 760-775.	7.3	21
5	Restorative effect of adipose tissue-derived stem cells on impaired hepatocytes through Notch signaling in non-alcoholic steatohepatitis mice. <i>Stem Cell Research</i> , 2021, 54, 102425.	0.7	6
6	A case of traumatic diaphragmatic hernia that caused obstruction of middle hepatic vein. <i>Acta Hepatologica Japonica</i> , 2021, 62, 413-419.	0.1	0
7	Chronic liver disease enables gut <i>Enterococcus faecalis</i> colonization to promote liver carcinogenesis. <i>Nature Cancer</i> , 2021, 2, 1039-1054.	13.2	26
8	Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacy. <i>Regenerative Therapy</i> , 2021, 18, 97-101.	3.0	12
9	Characterization of adipose tissue-derived stromal cells of mice with nonalcoholic fatty liver disease and their use for liver repair. <i>Regenerative Therapy</i> , 2021, 18, 497-507.	3.0	2
10	Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver. <i>Liver Cancer</i> , 2020, 9, 261-274.	7.7	5
11	Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation. <i>Translational Oncology</i> , 2020, 13, 100777.	3.7	17
12	IL $\hat{2}^{8B}$ variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1813-1820.	2.8	2
13	Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 269-285.	4.5	14
14	A novel $\hat{1}^{\pm}$ -fetoprotein-derived helper T-lymphocyte epitope with strong immunogenicity in patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 4021.	3.3	6
15	Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. <i>Journal of Gastroenterology</i> , 2020, 55, 701-711.	5.1	16
16	Tumor lysis syndrome in a patient with metastatic melanoma treated with nivolumab. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 935-939.	0.8	7
17	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. <i>PLoS ONE</i> , 2020, 15, e0232089.	2.5	7
18	Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2020, 50, 871-884.	3.4	35

#	ARTICLE	IF	CITATIONS
19	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0
20	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0
21	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0
22	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0
23	Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Liver Cancer, 2019, 8, 130-139.	7.7	21
24	Characteristics of Immune Response to Tumor-Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma. Hepatology, 2019, 69, 653-665.	7.3	56
25	Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation. Clinical Journal of Gastroenterology, 2019, 12, 63-70.	0.8	4
26	Development of novel diagnostic system for pancreatic cancer, including early stages, measuring <scp>mRNA</scp> of whole blood cells. Cancer Science, 2019, 110, 1364-1388.	3.9	17
27	Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1829-1835.	2.8	18
28	Overuse of antianaerobic drug is associated with poor postchemotherapy prognosis of patients with hepatocellular carcinoma. International Journal of Cancer, 2019, 145, 2701-2711.	5.1	25
29	Characteristics of Impaired Dendritic Cell Function in Patients With Hepatitis B Virus Infection. Hepatology, 2019, 70, 25-39.	7.3	26
30	Biological characteristics of gene expression features in pancreatic cancer cells induced by proton and X-ray irradiation. International Journal of Radiation Biology, 2019, 95, 571-579.	1.8	7
31	Hepatic arterial infusion chemotherapy after sorafenib treatment in patients with advanced hepatocellular carcinoma who are unfit for regorafenib.. Journal of Clinical Oncology, 2019, 37, 355-355.	1.6	1
32	Immune response to human telomerase reverse transcriptase-derived helper T cell epitopes in hepatocellular carcinoma patients. Liver International, 2018, 38, 1635-1645.	3.9	7
33	Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B. Journal of Gastroenterology, 2018, 53, 740-751.	5.1	17
34	Immune responses against tumour-associated antigen-derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients. Liver International, 2018, 38, 2040-2050.	3.9	13
35	Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy. Hepatology Research, 2018, 48, 956-966.	3.4	39
36	Immune responses of human T lymphocytes to novel hepatitis B virus-derived peptides. PLoS ONE, 2018, 13, e0198264.	2.5	9

#	ARTICLE	IF	CITATIONS
37	Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2018, 13, e0191026.	2.5	32
38	Surrogacy of time to progression for overall survival in advanced hepatocellular carcinoma treated with systemic therapy: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 403-403.	1.6	0
39	Association Between High-Avidity T-Cell Receptors, Induced by Î±-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2017, 152, 1395-1406.e10.	1.3	61
40	Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2017, 6, 236-249.	7.7	24
41	Prognosis of type 1 autoimmune pancreatitis after corticosteroid therapy-induced remission in terms of relapse and diabetes mellitus. <i>PLoS ONE</i> , 2017, 12, e0188549.	2.5	27
42	Cellular Immune Responses for Squamous Cell Carcinoma Antigen Recognized by T Cells 3 in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2017, 12, e0170291.	2.5	13
43	Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2016, 16, 338.	2.6	12
44	Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. <i>Hepatology Research</i> , 2016, 46, 650-656.	3.4	66
45	Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Cancer Science</i> , 2016, 107, 1263-1269.	3.9	22
46	Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 715-725.	4.2	58
47	Response to Importance of confounding factors in assessing fatty acid compositions in patients with non-alcoholic steatohepatitis. <i>Liver International</i> , 2015, 35, 1773-1773.	3.9	7
48	Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma. <i>Cancer Letters</i> , 2015, 364, 98-105.	7.2	31
49	Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. <i>Hepatology Research</i> , 2015, 45, 949-959.	3.4	40
50	Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma. <i>Cancer Letters</i> , 2015, 369, 242-249.	7.2	37
51	Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2006, 43, 1284-1294.	7.3	102